Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
values decrease » values increased (Expand Search)
linear decrease » linear increase (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
values decrease » values increased (Expand Search)
linear decrease » linear increase (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
-
901
Time Course of the RAAS.
Published 2025“…REN levels increased significantly from baseline at 1-month visit (4.15 ± 7.35 vs. 2.75 ± 8.03 ng/L; DKD vs. non-DKD; between-group difference, <i>p</i> < 0.05), while ARR values decreased significantly from baseline at 1-month visit (−0.70 ± 1.16 vs. −0.59 ± 1.19; between‑group difference, <i>p</i> > 0.05) and 3-month visit (−0.45 ± 1.15 vs. −0.42 ± 1.07; between‑group difference, <i>p</i> > 0.05) in both groups (within‑group change vs. baseline, <i>p</i> < 0.017). …”
-
902
-
903
Data Sheet 2_Modeling Krebs cycle from liver, heart and hepatoma mitochondria, supported Complex I as target for specific inhibition of cancer cell proliferation.pdf
Published 2025“…</p>Results<p>The enzymes Vmax values were higher in the following order: RHM > HepM > RLM; meanwhile, Km values were similar. …”
-
904
Data Sheet 1_Modeling Krebs cycle from liver, heart and hepatoma mitochondria, supported Complex I as target for specific inhibition of cancer cell proliferation.pdf
Published 2025“…</p>Results<p>The enzymes Vmax values were higher in the following order: RHM > HepM > RLM; meanwhile, Km values were similar. …”
-
905
-
906
Apoptosis inhibitor prevented the decrease of IIL ESP-induced TJs expression and alleviated barrier disruption of Caco-2 monolayer.
Published 2025“…<p><b>A:</b> Apoptosis inhibitor Z-VAD-FMK pretreatment increased the IIL ESP-decreased TEER. …”
-
907
-
908
-
909
-
910
-
911
Analyses comparing renal sinus fat at 24-months between the placebo and statin groups.
Published 2025Subjects: -
912
-
913
-
914
-
915
Baseline demographic and clinical characteristics of women with breast cancer.
Published 2025Subjects: -
916
-
917
-
918
-
919
-
920